{"filing":{"accession_number":"0001575872-26-000715","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-21","primary_document":"rdy0949_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000715/rdy0949_6k.htm"},"events":[{"id":36562,"run_id":33710,"accession_number":"0001575872-26-000715","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Dr. Reddy's announced receipt of DCGI (Drugs Controller General of India) regulatory approval for Zytorvi® (toripalimab) in advanced esophageal squamous cell carcinoma, marking the drug's second approved indication in India. This is a material regulatory milestone and product expansion event that would affect investor assessment of the company's oncology portfolio growth and market access, but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or financial obligations. It is clearly operational/strategic in nature—a regulatory approval enabling commercial expansion of an existing licensed product.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":41017,"accession_number":"0001575872-26-000715","item_number":"EX-99.1","item_title":"rdy0949_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's announced receipt of DCGI (Drugs Controller General of India) regulatory approval for Zytorvi® (toripalimab) in advanced esophageal squamous cell carcinoma, marking the drug's second approved indication in India. This is a material regulatory milestone and product expansion event that would affect investor assessment of the company's oncology portfolio growth and market access, but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or financial obligations. It is clearly operational/strategic in nature—a regulatory approval enabling commercial expansion of an existing licensed product.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:21:38.117221+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":41017,"accession_number":"0001575872-26-000715","item_number":"EX-99.1","item_title":"rdy0949_ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Dr. Reddy's announced receipt of DCGI (Drugs Controller General of India) regulatory approval for Zytorvi® (toripalimab) in advanced esophageal squamous cell carcinoma, marking the drug's second approved indication in India. This is a material regulatory milestone and product expansion event that would affect investor assessment of the company's oncology portfolio growth and market access, but does not fit the specific event categories of earnings release, M\u0026A, executive changes, or financial obligations. It is clearly operational/strategic in nature—a regulatory approval enabling commercial expansion of an existing licensed product.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:21:38.117221+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-21"}]}